GE Aerospace Unveils $300M Modernization Plan for Singapore Repair Facility
GE Aerospace is investing $300 million from 2025 to 2029 to modernize the Singapore engine repair facility with advanced automation, digitization and AI inspection to accelerate turnaround and improve safety, quality and cost. Backed by the Singapore Economic Development Board, the upgrade expands APAC MRO capacity and high-pressure turbine repairs.
1. GE Medical Holding Exercises Warrants and Infuses NOK 33 Million
On February 5, 2026, GE Medical Holding AB, a subsidiary of GE HealthCare Technologies Inc., confirmed the exercise of all 26,973,169 warrants issued in connection with EXACT Therapeutics’ December 2024 private placement. The transaction will deliver gross proceeds of NOK 33 million to EXACT Therapeutics, immediately bolstering the company’s cash position. Remaining warrant holders have until February 26, 2026 to decide on subscription, potentially unlocking additional capital for clinical activities.
2. Phase 2 ENACT Trial Safety Read-Out and Early Efficacy Signals
EXACT Therapeutics’ Trial Monitoring Committee issued a positive conclusion on the pre-planned safety read-out from its phase 2 ENACT trial in locally advanced pancreatic cancer, clearing the way for continued patient dosing. Preliminary unaudited data show early, encouraging tumor shrinkage and a greater than 85% decline in the CA 19-9 tumor biomarker among evaluable patients. These early efficacy signals may enhance investor confidence ahead of fully audited read-outs and could accelerate partner engagement.
3. Strategic Implications for Collaboration and Cash Runway
The NOK 33 million infusion from GE Medical Holding strengthens EXACT Therapeutics’ balance sheet and extends its cash runway through key clinical milestones. CEO Karley Yoder of GE HealthCare’s Comprehensive Care Ultrasound unit reiterated GE’s commitment to the ultrasound-activated PS101 platform, highlighting potential synergies in oncology applications. With additional warrant exercises possible and positive trial momentum, EXACT Therapeutics is positioned to negotiate further strategic collaborations or follow-on financings before the end of Q2 2026.